Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
Shots:
- The approval is based on P-III EMBRACA study results assessing Talzenna (qd- 1mg) vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) in 431 patients in ratio (2:1) with inherited BRCA1/2 mutation & LA or m-triple-negative or HR+/HER2- breast cancer- prior treated with 3L CT regimen
- The P-III EMBRACA study results: mPFS (8.6 mos.vs 5.6mos.); ORR (62.6% vs 27.2%); 46% reduction in the risk of disease progression
- Talzenna is a PARP inhibitor- being evaluated in multiple studies for breast and other cancers- including early triple-negative breast cancer and prostate cancer and has received FDA’s approval for gBRCAm HER2-- LA or m-breast cancer
Click here to read full press release/ article | Ref: Pfizer | Image: Q Costa Rica
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com